

Organogenesis CEO joins Massachusetts Biotechnology Council Board

15 May 2018 | News

MassBio is a not-for-profit organization representing more than 1,000 biotechnology companies, service organizations, research institutions and hospitals. The MassBio Board of Directors comprises a select group of life sciences leaders committed to guiding the organization in its mission to grow Massachusetts' life sciences industry, add value to the healthcare system and improve patient lives.



Organogenesis has announced that Gary S. Gillheeney, Sr., President and CEO of Organogenesis Inc., has been appointed to the Massachusetts Biotechnology Council (MassBio) Board of Directors for the 2018-2019 term.

"We need the best and brightest to guide us through new challenges and opportunities in the life sciences industry, which is why we're thrilled to welcome Gary Gillheeney to the MassBio Board of Directors," said Robert K. Coughlin, President and CEO of MassBio. "Gary's leadership experience at the helm of Organogenesis will be a great asset to MassBio as we work to bring further value to our member organizations and the individuals we serve."

MassBio is a not-for-profit organization representing more than 1,000 biotechnology companies, service organizations, research institutions and hospitals. The MassBio Board of Directors comprises a select group of life sciences leaders committed to guiding the organization in its mission to grow Massachusetts' life sciences industry, add value to the healthcare system and improve patient lives.

"I'm honored to serve on the MassBio board," said Gillheeney. "I look forward to working with other Massachusetts life sciences leaders to highlight the value our innovations bring to patients, the healthcare system and our state and national economies."

Gillheeney brings to the MassBio Board of Directors significant expertise in the medical device and biotechnology spaces. Under Gillheeney's leadership, Canton-based Organogenesis Inc. has grown to its current position as a leading regenerative medicine company offering a portfolio of products for the advanced wound care and surgical biologics markets. For his work at Organogenesis, Mr. Gillheeney was recognized as an "Entrepreneur of the Year" by Ernst & Young.